How long are Pelage going to milk the phase 2a results of PP405?
    1/18/2026

    From the encyclopedia
    PP405 →

    mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

    Clascoterone →

    Topical androgen-receptor blocker, approved as an acne cream

    At a glance
    In this general discussion post the tone is 😞 negative.

    Other terms

    PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.
    View this post in the Community →

    Similar Community Posts Join

    6 / 6 results

      community Are these new hair loss treatments ever gonna release?

       43 upvotes 6 months ago
      Hair loss treatments like Breezula and PP405 are delayed, with approvals taking years, while existing treatments like minoxidil and finasteride remain popular. New treatments like Clascoterone and Veradermics are in trials, but high costs and lengthy approval processes slow their release.

      community OND-1 "Cyclosporine A” New hair loss treatment

      in Research/Science  28 upvotes 5 months ago
      Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

      community The future of hair loss drugs.

       34 upvotes 7 months ago
      Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.

      community What new hair-loss treatments actually look exciting right now (Oct 2025)

       171 upvotes 11 months ago
      New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

    Related Research

    6 / 6 results

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.

      research Emerging pharmacotherapies for Androgenetic Alopecia

      June 2026 in “Expert Opinion on Pharmacotherapy”
      This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

      research PP405 in Alopecia: An Emerging Molecule worth Investigating

      January 2026 in “Journal of Community Medicine and Health Solutions”
      In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.